HemoSonics
Robert A. Roda (Bob) joined HemoSonics in February 2020 as the company’s President and CEO, bringing more than 25 years of global experience developing and commercializing innovative diagnostic and medical device products and services.
Most recently Bob Roda served as President and CEO of Menarini Silicon Biosystems, Inc, a diagnostic and biotech company focused on the use of liquid biopsy and predictive diagnostic tests for the treatment of cancer patients. Prior to that position he was Vice President and General Manager at Becton Dickinson where he led the medical and procedural solutions business in the US. From 1998-2012, Bob held positions of increasing responsibility at Johnson & Johnson in both the medical device and diagnostic sectors, with his last role being WW VP Marketing in Immunohematology, Donor Screening and Clinical Laboratories at Ortho Clinical Diagnostics, a J&J company. Bob earned a Bachelor of Arts degree in Economics from the University of Rhode Island and completed post graduate course work at Kellogg Graduate School of Management.
This person is not in any offices
HemoSonics
1 followers
HemoSonics, LLC is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care.